Our research aims to understand the cellular mechanisms of how blood clots are formed and what leads to stabilisation of blood clots.
Our research also involves identification and development of novel inhibitors of blood clot formation. The research of Professor Jackson and her team ranges from work on the cellular, molecular, physiological and biochemical aspects of thrombosis, to small animal models of in vivo thrombus formation and ischaemic stroke. In addition, research of this team examines the importance of cell surface receptors known as immunoreceptors and tetraspanins. Furthermore, investigation of the role of tyrosine kinase inhibitors in regulating platelet thrombus formation.
- To study mechanisms that regulate platelet thrombus formation in mouse models.
- To gain knowledge on the importance of tetraspanins and immunoreceptors in regulating blood clots.
- To study mechanisms of signalling and compartmentalisation in platelet responsiveness.
- To understand the role of tyrosine kinase inhibitors in regulating blood clots.
- To investigate the role of natural chinese and aboriginal medicines in regulating blood clot formation.
- Professor Denise Jackson, Laboratory Head
- Dr Cindy O’Malley, Senior Lecturer, Haematology
- Mrs Genia Burchall, Lecturer, Haematology
- Dr Faith Kwa, Lecturer, Laboratory Medicine
- Dr Daniel Sze, Senior Lecturer, Laboratory Medicine
- Mr Musaed Alshahrani, PhD student
- Mr Mohammed Makkawi, PhD student
- Mr Naif Al Hawiti, PhD student
- Ms Kamaliah Rijal, PhD student
- Mr Abdullah Hamadi, PhD student
- Professor Leonie Ashman University of Newcastle
- Associate Professor Mark Wright, Monash University
- Professor Nicole Beauchemin, McGill University, Montreal, Canada
- Associate Professor Heyu Ni, St. Michael’s Hospital
- Dr Odilia Wijburg, University of Melbourne
- Professor Sonia Najjar, Ohio University, Toledo, USA
- Perpetual Trustees Project Grant: $65,000. “An investigation of the adverse vascular and thrombotic effects of the tyrosine kinase inhibitors, nilotinib and ponatinib. Chief investigators: Jackson DE, Grigg A, Kwa F.
- The Marian and EH Flack Trust: $20,000. P2Y12 purinergic receptor and tetraspanins, CD151 and TSSC6 provide an essential link for stable thrombus formation. Jackson DE.
- Diabetes Australia: $50,000. Linden M. Aspirin resistance.
- Carlton Football $28,000. Markers of inflammation and immune function during training and competition of AFL football. Coffey V, Linden MD.
- Sir Edward Dunlop Medical Research Foundation $15,000. “Understanding platelet immunoreceptors in contact-dependent events that modulate platelet thrombus formation“. Jackson DE.
- NHMRC Project Grant APP1010939 Fraser J, Fung YL, Jackson DE, Semple J, Bidstrup B and Schribler A. “The unholy alliance between extracorporeal circuitry and transfusion medicine characterising inflammation and injury (2011-2013) $926,299/3 years.
- NHMRC Project Grant (#603812) Jackson DE, Wright MD and Ashman LK. $568,000 for 3 years. “Tetraspanins serve as molecular facilitators to regulate platelet thrombus formation“. (2010-2012).
- NHF Grant-in-Aid (#603813)(G09M 4360) Jackson DE, Beauchemin N. $129,000 for 2 years. “Contact dependent control of thrombogenesis mediated by immunoreceptors. (2010-2011).
- Rebecca Cooper Medical Research Foundation: $20,000. “Stabilisation of blood clots-implications for cerebral ischaemic stroke“. Jackson DE.
- William Angliss (Victoria) Charitable Trust $1,000. “Thrombosis and Vascular Disease“. Jackson DE (2010).
- Ian Potter Foundation $100,000. “Establishment of a Clinical Flow Cytometry Core Facility“. Linden MD.
- National Heart Foundation Grant-in-Aid G08M 3768 Jackson DE. $130,000/2 years. “Signalling mechanisms that regulate platelet thrombus formation and growth (2009-2010).
Understanding platelet immunoreceptors in contact-dependent events that modulate platelet thrombus formation
Receptors that invoke opposing intracellular signalling effects are considered essential for maintaining a balance between activation and quiescence of the immune system. This conceptual model may also be involved in the regulation of haemostasis and thrombosis. While the ITAM and ITIM signalling as a major means of activating and inhibiting platelets has been established by studies on GPVI-FcR gamma chain collagen receptor and PECAM-1, our understanding of immunoreceptor signalling in the context of haemostasis and thrombosis is at an early stage. Prof. Jackson’s team demonstrated a novel for Ceacam1 and Ceacam2 serving as a negative regulator of platelet-collagen interactions involving GPVI receptor and CLEC-2 and in thrombus growth in vitro and in vivo.
Tetraspanins serve as molecular facilitators to regulate platelet thrombus formation
Tetraspanin superfamily members, CD151 and TSSC6 act by augmenting ’outside-in’ (ligand-occupied) integrin alphaIIbbeta3 signaling but not agonist-induced activation of ’inside-out’ integrin alphaIIbbeta3 signaling. The presence of tetraspanins, CD151 and TSSC6 in tetraspanin-integrin alphaIIbbeta3 complexes may be important for maintaining stable platelet adhesive interactions in platelet thrombus formation in vivo. Our study was designed to determine the role of CD151 and TSSC6 in platelet thrombus formation in vivo and define the contribution of platelet versus endothelial CD15 in regulating platelet thrombus formation in vivo. Our data provides evidence for a pivotal involvement of platelet CD151 in the regulation of thrombus stability in vivo in the context of microvascular and arteriolar thrombosis.
Plaque stability and atherothrombosis-role of cell surface receptors
Atherothrombosis is a major cause of cardiovascular events. Animal models are now available to study acute thrombus formation by plaque rupture to study athero thrombosis by intravital fluorescence microscopy. What factors are important in plaque stability in atherosclerosis is still poorly defined. In this project, we will examine the importance of cell-contact dependent events in the modulation of plaque stability in atherothrombosis using a mouse model.
Characterisation of novel anti-platelet agents
The Thrombosis and Vascular Diseases Laboratory has many active collaborations with both academic research groups with industry to characterise the anti-platelet potential and mechanism of novel and emerging therapeutic agents. These include the highly active marine fish oil Lyprinol, novel synthetic flavonoids, chinese herbal medicines, aboriginal medicines and a gaseous mediator hydrogen sulphide. For enquiries about academic or commercial colloborators please contact Professor Denise Jackson - phone +61 3 9925 7392 or email email@example.com.
Why not join us?
All enquiries about joining us as honours and postgraduate students or as postdoctoral Fellows should be directed to Denise Jackson.